- Take the Pneumonia Quiz
- The Common Cold Slideshow Pictures
- Bronchitis Slideshow Pictures
- Patient Comments: Pneumococcal Vaccination - How Often?
- Patient Comments: Pneumococcal Vaccination (Pneumonia Vaccine) - Side Effects
- What is pneumococcal vaccination?
- Who should consider pneumococcal vaccination?
- Who should not receive pneumococcal vaccine? What about pregnancy?
- How is pneumococcal vaccine administered?
- What are side effects of pneumococcal vaccine?
- What if it is not clear what a person's vaccination history is?
- How long must a person wait to receive other vaccinations?
- Vaccination of children recommended
- What are the current recommendations for administration of pneumococcal vaccine in healthy adults?
Who should not receive pneumococcal vaccine? What about pregnancy?
The pneumococcal vaccine should not be received by people with a prior history of hypersensitivity reactions to the vaccine.
The safety of the pneumococcus vaccine for pregnant women has not yet been studied. There is no evidence that the vaccine is harmful to either the mother or the fetus, but pregnant women should consult with their doctor before being vaccinated. Women who are at high risk of pneumococcal disease should be vaccinated before becoming pregnant, if possible.
How is pneumococcal vaccine administered?
The pneumococcal vaccine is given as a single injection in adults. The vaccine is injected as a liquid solution of 0.5 mL into the muscle (intramuscular or IM), typically deltoid muscle, or under the skin (subcutaneous or SC). The area injected is typically disinfected by rubbing alcohol onto the skin prior to the injection. The conjugated Prevnar 13 vaccine is given as a series of four injections in children.
People vaccinated prior to age 65 should be vaccinated at age 65 if five or more years have passed since the first dose. For people with a lack of spleen function (such as in sickle cell disease or after spleen removal), transplant patients, patients with chronic kidney disease, immunosuppressed or immunodeficient people, and others at highest risk of fatal infection, a second dose should be given at least five years after first dose.